

Test Specific Guidelines



CADASIL Genetic Testing

MOL.TS.144.A v1.0.2023

Introduction

CADASIL genetic testing is addressed by this guideline.

Procedures Addressed

The inclusion of any procedure code in this table is provided for informational purposes and is not a guarantee of coverage nor an indication that prior authorization is required.

Procedures addressed by this guideline	Procedure codes
NOTCH3 Deletion/Duplication Analysis	81479
NOTCH3 Known Familial Mutation Analysis	<u>81403</u>
NOTCH3 Targeted Sequencing	81406

What Is CADASIL?

Definition

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is an adult-onset form of cerebrovascular disease. There are no generally accepted clinical diagnostic criteria for CADASIL and symptoms vary among affected individuals.

Prevalence

CADASIL is a rare disease. The exact prevalence is unknown. CADASIL is probably still underdiagnosed. The minimum prevalence is estimated to be between 2-5 per 100,000 based on multiple small and national registries.^{1,2} More recent "reports suggest that the prevalence of NOTCH3 cysteine-altering pathogenic variants is substantially higher, and may be as high as 1 in 300 worldwide."³ A founder effect has been reported for Finnish individuals and individuals in the Marche region of Italy.¹

CADASIL is the most prevalent inherited cause of cerebral small-vessel disease.⁴



Symptoms

Typical signs and symptoms include^{1,3,5}

Transient ischemic attacks and ischemic stroke, occurs at a mean age of 47 years (age range 20-70 years), in most cases without conventional vascular risk factors

- <u>cognitive disturbance, primarily affecting executive function, may start as</u> <u>early as age 35 years</u>
- psychiatric or behavioral abnormalities
- <u>migraine with aura, occurs with a mean age of onset of 30 years (age range 6-48 years), and</u>

Less common symptoms include:

- recurrent seizures with onset in middle age, usually secondary to stroke
- acute encephalopathy, with a mean age of onset of 42 years

<u>Cause</u>

CADASIL is an autosomal dominant disease caused by mutations in the NOTCH3 gene.

To date, NOTCH3 is the only gene in which mutations are known to cause CADASIL.¹ NOTCH3 has 33 exons. CADASIL pathogenic variants occur in exons 2–24, which encode the 34 epidermal growth factor repeats (EGFR).^{1,6} The majority of pathogenic variants occur in exons 2-6.³ NOTCH3 encodes a transmembrane receptor that is primarily expressed in vascular smooth-muscle cells, preferentially in small arteries.¹ "In CADASIL, the extracellular domain of the Notch3 receptor accumulates within blood vessels. Accumulation takes place at the cytoplasmic membrane of VSMCs [vascular smooth muscle cells] and pericytes in close vicinity to the granular osmiophilic deposits (GOM) that characterize the disease. NOTCH3 recruits other proteins into the extracellular deposits, among them vitronectin and tissue inhibitor of metalloproteinase-3 (TIMP3), which may be relevant for disease pathogenesis."³ There is a hypothesis that structural abnormalities in the vascular smooth-muscle protein NOTCH3 trigger arterial degeneration, vascular protein accumulation, and cerebrovascular failure.⁴

No clear genotype-phenotype correlations exist for individuals with CADASIL.^{7,8} Some studies describe phenotype-genotype correlations. "There is reasonably strong evidence that pathogenic variants in the first six epidermal growth factorlike repeat domains (EGFR 1 to 6) of the Notch3 protein are associated with an earlier age of stroke onset, a more severe phenotype, and lower survival compared with pathogenic variants in EGFR 7 to 34."³ However, there can be significant intrafamilial variability with the age of onset, disease severity, and disease progression. The genotype cannot be used to predict the phenotype.^{1,4} NOTCH3 cysteine-altering pathogenic variants are associated with a broad phenotypic spectrum which includes classic CADASIL, mild small vessel disease, and non-penetrance.³

Inheritance

This describes autosomal dominant inheritance.

Autosomal dominant inheritance

In autosomal dominant inheritance, individuals have 2 copies of the gene and only one mutation is required to cause disease. When a parent has a mutation, each offspring has a 50% risk of inheriting the mutation. Males and females are equally likely to be affected.

Diagnosis

Brain Magnetic Resonance Imaging (MRI) findings include T2-signalabnormalities in the white matter of the temporal pole and T2-signalabnormalities in the external capsule and corpus callosum.^{1,3}

CADASIL is suspected in an individual with the clinical signs and MRI findings. A positive family history for stroke or dementia is also indicative of disease in symptomatic individuals. However, a negative family history should not exclude the diagnosis, as de novo mutations have been reported, and affected family members are frequently misdiagnosed.^{1,7}

Sequencing of all NOTCH3 exons encoding EGF–like domains fails to identify a mutation in up to 4% of individuals with CADASIL. Therefore, skin biopsy with histopathologic evaluation for characteristic GOM deposits is appropriate for individuals with a high index of clinical suspicion for CADASIL and negative genetic testing.^{2,3}

For a firm diagnosis of CADASIL, at least one of the following is required:

- Documentation of a typical NOTCH3 mutation by genetic analysis.^{1,3,7}
- <u>Documentation of characteristic GOM deposits within small blood vessels by</u> <u>skin biopsy.^{1,3,7}</u>

<u>Management</u>

A correct diagnosis of CADASIL is important because the clinical course of disease is different from individuals with other types of cerebral small-vessel disease and proven therapies for stroke have not been validated in individuals with CADASIL.⁷ However, no specific disease-modifying treatments for CADASIL exist. Management and treatment of individuals is generally symptomatic and supportive.^{1,3,5,7,9}



<u>Survival</u>

Life expectancy for men with CADASIL is reduced by approximately five years and for women by 1 to 2 years.²

Test Information

Introduction

<u>Testing for CADASIL may include genetic testing (known familial mutation</u> <u>analysis, sequence analysis, or deletion/duplication analysis) and/or skin biopsy.</u>

<u>Skin Biopsy</u>

A pathognomonic characteristic of CADASIL is the finding of characteristic GOM within the vascular media and increased NOTCH3 staining of the arterial wall, which can be evaluated in a skin biopsy.¹ Specificity of skin biopsy findings is high, as the characteristic deposits have not been documented in any other disorder. Sensitivity has been reported to range from 45%-100%. Sensitivity and specificity can be maximized to >90% by immunostaining for NOTCH3 protein.⁷ When interpreted by an experienced (neuro) pathologist, combined analysis by electron microscopy and immunohistochemistry usually allows for a conclusive CADASIL diagnosis.

Known Familial Mutation (KFM) Testing

Known familial mutations analysis is performed when a causative mutation has been identified in a close biological relative of the individual requesting testing. Analysis for known familial mutations typically includes only the single mutation. However, if available, a targeted mutation panel that includes the familial mutation may be performed.

Sequence Analysis

NOTCH3 mutation detection may reach >95% in individuals with strong clinical suspicion of CADASIL¹. To date, all mutations in NOTCH3 causing CADASIL have been in exons 2-24, including intron-exon boundaries.¹ In the United States, laboratories offering CADASIL testing appear to perform, at minimum, sequencing of exons 2-24 at the time of this review.

Deletion and Duplication Analysis

Analysis for deletions and duplications can be performed using a variety of technical platforms including exon array, Multiplex ligation-dependent probe amplification (MLPA), and NGS data analysis. These assays detect gains and losses too large to be identified through standard sequence analysis, often single or multiple exons or whole genes.

Large deletions and duplications in the NOTCH3 gene have not been reported.³ Molecular testing approaches can include deletion/duplication analysis if sequencing analysis of NOTCH3 is unrevealing.¹

Guidelines and Evidence

Introduction

This section includes relevant guidelines and evidence pertaining to CADASIL testing. No evidence-based U.S. testing guidelines have been identified.

European Academy of Neurology

The European Academy of Neurology (EAN, 2020) consensus panel stated:⁹

- <u>"CADASIL can only be definitively confirmed by genetic testing, revealing a</u> <u>NOTCH3 mutation altering the number of cysteines in one of the 34 EGFr</u> <u>domains of the NOTCH3 protein."</u>
- <u>A diagnosis of CADASIL can be established by skin biopsy with electron</u> <u>microscopy showing GOM, but genetic testing should be the first diagnostic</u> <u>line of investigation.</u>
- <u>"In the case of a NOTCH3 variant of unknown significance, CADASIL can be</u> <u>confirmed using a skin biopsy for electron microscopy and/or NOTCH3</u> <u>immunostaining."</u>
- <u>"All or almost all variants leading to CADASIL result in a loss or gain of a cysteine in EGFr repeats. Some non-cysteine-changing variants have been reported but the consensus was that the vast majority of these variants are not pathogenic. In such cases, electron microscopy revealing GOM can be a useful diagnostic tool."</u>
- <u>"The diagnosis of CADASIL should be considered in any patient with</u> <u>unexplained symmetrical periventricular WMHs [white matter hyperintensities]</u> <u>and a positive family history of migraine with aura, stroke, mood disorders or</u> <u>dementia."</u>

Selected Relevant Publications

The following publications addressed CADASIL testing.

Pescini et al (2012)

Pescini et al (2012) published a scale to help guide clinicians in selecting individuals for NOTCH3 genetic analysis due to a high probability of a CADASIL genetic diagnosis. This scale assigns weighted scores to common features of CADASIL. The authors state that their scale is accurate, demonstrating optimal sensitivity (96.7%) and specificity (74.2%). At the time of publication, results needed to be confirmed and further validated.¹⁰



Choi et al (2010)

A two-center cohort study found that blood pressure and hemoglobin A1c levels were associated with cerebral mini bleeds in individuals with CADASIL.⁷ Therefore, controlling blood pressure and glucose levels may improve the clinical course of the disease. It is also reasonable to control for high cholesterol and high blood pressure given the high rate of ischemic stroke seen in CADASIL.⁷

Tikka et al (2009)

Evidence from a 2009 retrospective cohort study suggested that an adequate skin biopsy for analysis of granular osmophilic material is a cost effective way to determine a diagnosis of CADASIL in symptomatic individuals.11

<u>The authors suggest that biopsy results can be used to guide the decision for</u> who should have genetic testing, particularly in individuals with no known familial mutation or from ethnic populations with no evidence of founder mutations.11

Clinical Utility

Patients with CADASIL should avoid anticoagulants, angiography, and smoking to avoid disease-related complications, so clinical utility is represented.^{1,7} Because of the risk for cerebral hemorrhage, use of antiplatelets rather than anticoagulants is considered for prevention of ischemic attacks. Evidence against the use of intravenous tissue plasminogen activator (IV tPA) has been suggested due to the possibility of hemorrhage; however, this is not conclusive.¹² Statins are used for treatment of hypercholesterolemia and antihypertensive drugs are used for hypertension and hypertension treatment may have an additional benefit.³ Management of neurologic events (migraines, depression, psychiatric manifestations) by a neurologist or neuropsychiatrist can be beneficial; pregnancy and postpartum periods are potential risk factors.¹

<u>Criteria</u>

Introduction

Requests for CADASIL testing are reviewed using these criteria.

Known Familial Mutation Testing

- Genetic Counseling:
 - <u>Pre and post-test genetic counseling by an appropriate provider (as</u> <u>deemed by the Health Plan policy), AND</u>
- <u>Previous Genetic Testing:</u>

- <u>No previous genetic testing for NOTCH3 mutations that would detect the</u> <u>familial mutation, AND</u>
- Predictive Testing:
 - <u>Member has a first-degree relative (i.e. parent, sibling, child) with an</u> <u>identified NOTCH3 gene mutation, and</u>

AmeriHealth Caritas

- Member is at least 18 years of age, OR
- Diagnostic Testing for Symptomatic Individuals:
 - <u>Member has a first-degree relative (i.e. parent, sibling, child) with an</u> <u>identified NOTCH3 gene mutation, and</u>
 - <u>High index of suspicion for CADASIL diagnosis based on clinical findings,</u> <u>AND</u>
- <u>Rendering laboratory is a qualified provider of service per the Health Plan</u> policy.

NOTCH3 Targeted Sequencing

- Genetic Counseling:
 - Pre and post-test genetic counseling by an appropriate provider (as deemed by the Health Plan policy), AND
- Previous Genetic Testing:
 - No previous genetic sequencing for NOTCH3 mutations, AND
- Diagnostic Testing for Symptomatic Individuals:
 - High index of suspicion for CADASIL diagnosis based on clinical findings, <u>AND</u>
- <u>Rendering laboratory is a qualified provider of service per the Health Plan</u> policy.

NOTCH3 Deletion/Duplication Analysis

- Member meets the above criteria for NOTCH3 targeted sequencing, AND
- NOTCH3 targeted sequencing performed and detected no mutations, AND
- No previous NOTCH3 deletion/duplication analysis

References

Introduction

These references are cited in this guideline.

- 1. <u>Hack RJ, Rutten J, Lesnik Oberstein SAJ. CADASIL. 2000 Mar 15 [Updated</u> 2019 Mar 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. <u>GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle;</u> 1993-2021. Available at https://www.ncbi.nlm.nih.gov/books/NBK1500/
- 2. <u>Dichgans M. (Updated July 2021). Cerebral Autosomal Dominant Arteriopathy</u> with Subcortical Infarcts and Leukoencephalopathy (CADASIL). [e-literature review]. UpToDate[®], 2021. Available by subscription online: http://www.uptodate.com/home/index.html.
- 3. <u>Di Donato I, Bianchi S, De Stefano N, Dichgans M, Dotti MT, Duering M,</u> <u>Jouvent E, Korczyn AD, Lesnik-Oberstein SA, Malandrini A, Markus HS,</u> <u>Pantoni L, Penco S, Rufa A, Sinanović O, Stojanov D, Federico A. Cerebral</u> <u>Autosomal Dominant Arteriopathy with Subcortical Infarcts and</u> <u>Leukoencephalopathy (CADASIL) as a model of small vessel disease: update</u> <u>on clinical, diagnostic, and management aspects.*BMC Med.* 2017 Feb 24;15(1):41. doi: 10.1186/s12916-017-0778-8.</u>
- 4. <u>Cramer J, White ML. Cerebral Autosomal Dominant Arteriopathy (CADASIL)</u> [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan. Available at: <u>https://www.ncbi.nlm.nih.gov/books/NBK470293/</u>
- 5. <u>Choi JC. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts</u> <u>and Leukoencephalopathy: A Genetic Cause of Cerebral Small Vessel</u> <u>Disease. J Clin Neurol. 2010;6:1-9</u>
- 6. Wang MM. CADASIL. Handb Clin Neurol. 2018;148:733-743. doi: 10.1016/B978-0-444-64076-5.00047-8.
- 7. <u>Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil.</u> <u>Lancet Neurol. Jul 2009;8(7):643-653.</u>
- 8. <u>Adib-Samii P, Brice G, Martin R, Markus H. Clinical Spectrum of CADASIL and</u> <u>the Effect of Cardiovascular Risk Factors on Phenotype: Study in 200</u> <u>Consecutively Recruited Individuals. *Stroke*. 2010;41:630-634.</u>
- 9. <u>Mancuso M, Arnold M, Bersano A, et al. Monogenic cerebral small-vessel</u> <u>diseases: diagnosis and therapy. Consensus recommendations of the</u> <u>European Academy of Neurology. *Eur J Neurol*. Jun 2020; 27(6):909-927.</u>
- 10. <u>Pescini F, Nannucci S, Bertaccini B, et al., The Cerebral Autosomal-Dominant</u> <u>Arteriopathy With Subcortical Infarcts and Leukoencepalopaty (CADASIL)</u> <u>Scale: a screening tool to select patients for NOTCH3 gene analysis. *Stroke.* <u>2012 Nov;43(11):2871-6.</u></u>
- 11. <u>Tikka S, Mykkanen K, Ruchoux MM, Bergholm R, Juanna M, Poyhonen M, Yki-Jarvinen H, Joutel A, Viitanen M, Baumann M, Kalimo H. Congruence Between NOTCH3 Mutations and GOM in 131 CADASIL Patients. *Brain.* 2009 <u>Apr;132(Pt4):933-9.</u></u>



12. <u>Khan TK, Murray A, Smith M, Successful Use of Intravenous Tissue</u> <u>Plasminogen Activator as Treatment for a Patient with Cerebral Autosomal</u> <u>Dominant Arteriopathy with Subcortical Infarcts and Leukencephalopathy: A</u> <u>Case Report and Review of Literature. J Stroke Cerebrovasc Dis. 2016</u> <u>Apr;25(4):53-57.</u>